• AIvolve Bio
  • Posts
  • AI-Powered Biotech Innovations: July 2024 Update

AI-Powered Biotech Innovations: July 2024 Update

Author

AIVOLVE BIO
July 02, 2024

AI-Powered Biotech Innovations: July 2024 Update

Founded in 2019 in the US, Athos Therapeutics is a clinical stage biotech company dedicated to developing AI-based precision therapeutics for autoimmune diseases and cancer. Their platform integrates medicinal chemistry and systems biology through machine learning, utilizing a biobank and a cloud-based infrastructure for various scientific analyses, including DNA, RNA, and protein extraction, as well as efficacy and safety studies on animal models.

The platform comprises several components:

  • RHEA: An integrated and automated transcriptomics tool.

  • TETHYS: An autonomous proteomics platform derived from LC-MS.

  • DIONE: A proprietary deep machine learning framework for patient molecular subtyping and precision therapeutic development.

Athos has over 25,000 human patient samples with clinical, pathological, and treatment outcome annotations from reputable sources like the Cleveland Clinic, The Crohn’s & Colitis Foundation, and Lahey Hospital & Medical Center.

Key assets include:

  • ATH-063: For inflammatory bowel diseases (IBD), lupus, and cancer, currently in Phase 1. This small molecule genomic regulator targets pro-inflammatory responses and promotes mucosal healing. The first patient was dosed on April 27, 2023, in Australia.

  • ATH-272: In preclinical phase for acute myeloid leukemia.

  • ATH-293, ATH-261, ATH-131: For atopic dermatitis, cancer, and autoimmune diseases, in preclinical phase.

  • ATH-301, ATH-501, ATH-601: In drug discovery for various conditions like fibrosis, multiple myeloma, rheumatoid arthritis, and eosinophilic esophagitis.

Athos recently announced the “Autonomization of their AI and ML Platforms” on March 5, 2024, and completed their first human clinical trial of ATH-063.

Founded in 2017, 3T Biosciences is an immunotherapy company specializing in T-cell receptor (TCR)-based therapeutics through its 3T-TRACE platform. This platform uses high-diversity target libraries combined with active machine learning to identify novel targets and TCRs for solid tumors.

Key developments include:

  • A strategic collaboration and licensing agreement with Boehringer Ingelheim announced on January 4, 2023, focused on next-generation cancer immunotherapies.

  • On March 7, 2024, 3T Biosciences announced additional collaborations with leading academic centers to enhance their 3T-TRACE platform.

3T Biosciences has raised $40M, backed by investors like Westlake Village BioPartners, Lightspeed Venture Partners, and the Parker Institute for Cancer Immunotherapy.

Arpeggio Biosciences, founded in 2017, combines proprietary biological assays with machine learning algorithms to analyze cellular dynamics post-drug treatment. Their GRETA™ platform sequences global mRNA more cost-effectively and rapidly than traditional methods, creating a vast database of chemotranscriptomics.

Pipeline highlights include:

  • NRF2 degrader: For lung cancer, showing tumor regression in vivo (April 2024).

  • GPX4 inhibitor: For sarcoma, combined with a checkpoint inhibitor (April 2024).

  • CKD treatment: By blocking ferroptosis in chronic kidney disease (May 29, 2024).

Arpeggio has raised $20.4M in funding.

Juvena Therapeutics, founded in 2017, focuses on decoding secreted proteins for chronic and age-related diseases using their AI-enabled JuvNET Platform. This platform integrates in silico, in vitro, and in vivo techniques for drug discovery.

Key assets include:

  • JUV-161: A recombinant fusion protein for myotonic dystrophy type 1, granted Orphan Drug designation by the FDA on January 23, 2024.

  • JUV-112: A preclinical obesity asset that enhances lipid metabolism without suppressing appetite.

Juvena Therapeutics has raised $52.7M.

Artivila Therapeutics

Founded in 2018 in China, Artivila Therapeutics leverages its AI platform, eLEAD, for innovative drug discovery. They focus on autoimmune diseases, neurodegenerative diseases, and cancers, with key programs including:

  • Ignite (ARD-885): In preclinical development for autoimmune diseases.

  • MM01 (ARD-198): In preclinical development for cancer.

Artivila has raised $22.8M.

Founded in 2014, Insilico Medicine offers the Pharma.AI platform, which encompasses tools for target discovery, drug design, and clinical trial outcome prediction. Key developments include:

  • INS018_055: In Phase 2 trials for idiopathic pulmonary fibrosis.

  • A novel QPCTL inhibitor for cancer immunotherapy, with the first patient dosed on May 15, 2024.

Insilico Medicine has also entered collaborations with Exelixis and Fosun Pharma.

Founded in 2013, BenevolentAI utilizes its Knowledge Graph for drug discovery and development. Their advanced pipeline includes:

  • BEN2293: For atopic dermatitis, which did not meet secondary efficacy measures in Phase IIa.

  • BEN-28010: A CHK1 inhibitor completing IND-enabling studies in 2024.

  • BEN-8744: Currently in Phase 1 for ulcerative colitis.

BenevolentAI has a strategic collaboration with AstraZeneca and has recently faced organizational changes, including layoffs and office closures.

Founded in 2012, Exscientia combines genetic data and machine learning for drug discovery. Notable achievements include:

  • EXS74539 (LSD1): With an IND submission expected in early 2024.

  • DSP-0038: In Phase I trials for Alzheimer's disease psychosis.

On May 21, 2024, Exscientia cut a quarter of its staff while preserving its AI-generated pipeline.

Founded in 2013, Lantern Pharma uses its RADR® platform to transform oncology drug discovery. Key assets include:

  • P-184: In a Phase I trial for solid tumors, with FDA clearance received in June 2023.

  • LP-284: For non-Hodgkin’s lymphoma, with the first patients dosed on March 15, 2024.

Lantern Pharma has also expanded its Harmonic™ Clinical Trial to Japan and Taiwan.

Founded in 2015, Verge Genomics uses its ConVERGE platform for drug discovery. Their lead candidate, VRG50635, targets ALS and has shown promising results in clinical development. Verge Genomics has formed strategic collaborations, including with Ferrer and Eli Lilly.

Until the next post ! Stay Curious, Stay Inspired.